Current Clinical Applications of PSMA-PET for Prostate Cancer Diagnosis, Staging, and Treatment
Cancers · 21.12.2024 · 16 (24) · 4263
DOI: 10.3390/cancers16244263 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 21.12.2024. Verfasst von Franz von Stauffenberg und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Over the past decade, prostate-specific membrane antigen positron emission tomography (PSMA-PET) has revolutionized prostate cancer (PCa) imaging, offering greater sensitivity and specificity compared to conventional imaging modalities such as CT, MRI, and bone scintigraphy. PSMA-PET is particularly valuable in staging newly diagnosed patients with intermediate- and high-risk disease, detecting biochemical recurrence, and evaluating metastatic cases. By utilizing radiotracers that accumulate specifically in PSMA-expressing cells, even small metastases can be detected, offering a detailed assessment of cancer extent and enabling more targeted diagnostic evaluations. Among the most utilized radiotracers, [68Ga]- and [18F]-labeled PSMA tracers enable precise imaging even with low disease burden. This diagnostic precision also supports advanced therapeutic approaches, including metastasis-directed therapy for oligometastatic cases and systemic treatment options, such as radioligand therapy, which presents new treatment perspectives for metastatic, castration-resistant PCa. This review examines the evolution of PSMA-PET in the diagnostics and therapy of PCa while comparing the current recommendations from leading clinical guidelines. The integration of PSMA-PET into clinical practice has redefined the management of PCa, improving diagnostic accuracy and enabling personalized treatment strategies, while lacking prospective long-term outcome data. As PSMA-PET continues to expand in clinical application, this review highlights its significant advancements while critically addressing limitations to ensure balanced and evidence-based implementation in prostate cancer care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
- Department of Urology, Stadtspital Triemli, 8063 Zurich, Switzerland.
- Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
ORCID-Profile: Franz von Stauffenberg, Alexander Maurer, Florian A Schmid
Zitieren
APA
von Stauffenberg, F., Poyet, C., Beintner-Skawran, S., Maurer, A., & Schmid, F. A. (2024). Current Clinical Applications of PSMA-PET for Prostate Cancer Diagnosis, Staging, and Treatment. Cancers, 16(24), 4263. https://doi.org/10.3390/cancers16244263
Vancouver
von Stauffenberg F, Poyet C, Beintner-Skawran S, Maurer A, Schmid FA. Current Clinical Applications of PSMA-PET for Prostate Cancer Diagnosis, Staging, and Treatment. Cancers. 2024;16(24):4263. doi:10.3390/cancers16244263
BibTeX
@article{vonStauffenberg2024,
author = {von Stauffenberg, Franz and Poyet, Cédric and Beintner-Skawran, Stephan and Maurer, Alexander and Schmid, Florian A},
title = {Current Clinical Applications of PSMA-PET for Prostate Cancer Diagnosis, Staging, and Treatment},
journal = {Cancers},
year = {2024},
volume = {16},
number = {24},
pages = {4263},
doi = {10.3390/cancers16244263}
}
EUVIMED